Clinical Trials · NCT07586865
Recombinant Human Thymosin Beta 4 for Injection(NL005) for Acute Myocardial Infarction
- Phase
- Phase 2
- Recruitment status
- Not Yet Recruiting
- Sponsor
- Beijing Northland Biotech. Co., Ltd.
- Enrollment
- 189
- Start date
- May 2026
- Locations
- 1 site, China
- Primary endpoint
- Myocardial Infarct Size (absolute) at Day 90